An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK

Aims  To determine the long‐term health economic benefits associated with lispro vs. regular human insulin (RHI) in UK Type 1 diabetic (T1DM) patients using the previously published and validated CORE Diabetes Model.

• Publication year

  2009

• Venue

  Diabetic Medicine

• Publication date

  2009-08-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/j.1464-5491.2009.02775.xPMID 19709151PMCID 3228293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries

  2012cited by this paper
• Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

  2009cited by this paper
• The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy

  2007cited by this paper
• The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

  2007cited by this paper
• Long-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness

  2007cited by this paper
• Predicting the Development of Macrovascular Disease in People with Type 1 Diabetes

  2006cited by this paper
• Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

  2006cited by this paper
• Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.

  2006cited by this paper
• Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

  2006cited by this paper
• Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.

  2005cited by this paper
• Vascular risk factors and diabetic neuropathy.

  2005cited by this paper
• Vascular risk factors and diabetic neuropathy.

  2005cited by this paper
• The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

  2004cited by this paper
• Effect of insulin lispro on glycaemic control in Chinese diabetic patients receiving twice-daily regimens of insulin.

  2004cited by this paper
• Validation of the CORE Diabetes Model against epidemiological and clinical studies.

  2004cited by this paper
• Treatment gap in the use of lipid‐lowering drug therapy in diabetes: a population‐based study

  2004cited by this paper
• Value-based medicine and vitreoretinal diseases

  2004cited by this paper
• Lipid levels and the use of lipid-lowering agents in England and Scotland

  2004cited by this paper
• Coverage in screening for diabetic retinopathy according to screening provision: results from a national survey in England and Wales

  2004cited by this paper
• Hypoglycaemia with insulin aspart: a double‐blind, randomised, crossover trial in subjects with Type 1 diabetes

  2004cited by this paper
• Real-life treatment of hypertension in UK primary care: prescribing habits, results and adherence to clinical guidelines

  2003cited by this paper
• Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus.

  2003cited by this paper
• Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus

  2003cited by this paper
• Effect of the rapid‐acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes

  2003cited by this paper
• Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

  2003cited by this paper
• The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)

  2003cited by this paper
• The cost‐effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes

  2003cited by this paper
• A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes

  2003cited by this paper
• Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.

  2002cited by this paper
• Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)

  2002cited by this paper
• Insulin Strategies for Primary Care Providers

  2002cited by this paper
• Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

  2002cited by this paper
• Basal‐bolus insulin therapy in Type 1 diabetes: comparative study of pre‐meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

  2002cited by this paper
• Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

  2002cited by this paper
• Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.

  2001cited by this paper
• Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin.

  2001cited by this paper
• Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

  2001cited by this paper
• Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin

  2001cited by this paper
• A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.

  2001cited by this paper
• Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.

  2001cited by this paper
• Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes.

  2001cited by this paper
• Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF‐I and IGFBP‐1 in type 1 diabetes

  2001cited by this paper
• Comparison between Insulin Aspart and Soluble Human Insulin in Type 1 Diabetes(IDDM) Patients Treated with Basal-Bolus Insulin Therapy : Phase III Clinical Trial in Japan

  2001cited by this paper
• One thousand health-related quality-of-life estimates.

  2000cited by this paper
• Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial

  2000cited by this paper
• Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.

  2000cited by this paper
• Cost effectiveness analysis of screening for sight threatening diabetic eye disease.

  2000cited by this paper
• Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction.

  2000cited by this paper
• A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.

  2000cited by this paper
• Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.

  2000cited by this paper
• Cost effectiveness analysis of screening for sight threatening diabetic eye disease

  2000cited by this paper
• Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

  1999cited by this paper
• Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

  1999cited by this paper
• Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.

  1999cited by this paper
• Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.

  1999cited by this paper
• Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study

  1999cited by this paper
• Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.

  1999cited by this paper
• Use of the short‐acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time‐interval injection‐meal

  1998cited by this paper
• Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External Pumps

  1998cited by this paper
• Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

  1998cited by this paper
• Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes

  1998cited by this paper
• The Effect of the Insulin Analog Lispro on Nighttime Blood Glucose Control in Type 1 Diabetic Patients

  1998cited by this paper
• Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus.

  1998cited by this paper
• The Epidemiology and Cost of Inpatient Care for Peripheral Vascular Disease, Infection, Neuropathy, and Ulceration in Diabetes

  1998cited by this paper
• Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40

  1998cited by this paper
• Improved glycemic control can be better maintained with insulin lispro than with human regular insulin

  1998cited by this paper
• Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?

  1998cited by this paper
• Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

  1997cited by this paper
• Insulin Lispro in CSII: Results of a Double-Blind Crossover Study

  1997cited by this paper
• Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro

  1997cited by this paper
• Health-Related Quality-of-Life Results From Multinational Clinical Trials of Insulin Lispro: Assessing benefits of a new diabetes therapy

  1997cited by this paper
• Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Metabolic Efficacy of Preprandial Administration of Lys(B28), Pro(B29) Human Insulin Analog in IDDM Patients: A comparison with human regular insulin during a three-meal test period

  1997cited by this paper
• Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

  1997cited by this paper
• Psychological status of diabetic people with or without lower limb disability.

  1996cited by this paper
• Emerging Standards for Diabetes Care from a City‐wide Primary Care Audit

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper

• Prandial Insulins: A Person-Centered Choice

  2024cites this paper
• Evaluating the Impact of Intensifying Treatment from Human to Analogue Insulin on Glycaemic Control and Insulin Expenditure in Patients with Type 2 Diabetes: A Retrospective Cohort Study

  2024cites this paper
• Facilitating the transition of young people with long-term conditions through health services from childhood to adulthood: the Transition research programme

  2019cites this paper
• How can health services contribute effectively and efficiently to facilitating transition of young people with long term conditions from childhood to adulthood? The Transition Research Programme

  2019cites this paper
• A cost of illness study evaluating the burden of Wolfram syndrome in the United Kingdom

  2019cites this paper
• Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus

  2017cites this paper
• Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

  2017cites this paper
• Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia.

  2016cites this paper
• Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia

  2016cites this paper
• Beneficios clínicos y económicos de la terapia con bomba de insulina integrada a sistema de monitoreo continuo de glucosa en los pacientes diabéticos tipo 1 en Colombia

  2016cites this paper
• Technology and Pregnancy

  2015cites this paper
• Drug delivery systems for the treatment of diabetes mellitus: state of the art.

  2013cites this paper
• Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline

  2013cites this paper
• A health economic analysis of clinical islet transplantation

  2012cites this paper
• Management of Diabetes Mellitus with Insulin Lispro

  2011cites this paper
• Glycemic Control and Perinatal Outcomes of Pregnancies Complicated by Type 1 Diabetes: Influence of Continuous Subcutaneous Insulin Infusion and Lispro Insulin

  2010cites this paper
• Diabetes in Pregnancy

  2010cites this paper
• Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia (cid:2)

  year unknowncites this paper